A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1 second (FEV1) in patients with mild-to-moderate persistent atopic asthma

Trial Profile

A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1 second (FEV1) in patients with mild-to-moderate persistent atopic asthma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2018

At a glance

  • Drugs PBF 680 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Palobiofarma
  • Most Recent Events

    • 15 Jun 2018 Status changed from planning to recruiting.
    • 13 Apr 2018 New trial record
    • 12 Apr 2018 According to a Palobiofarma media release, the company is planning to start this trial in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top